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Abstract We examined the dosing regimens, compliance,
and outcomes of premature infants who received palivizumab
within the Canadian Registry of Palivizumab (CARESS).
Infants receiving ≥1 dose of palivizumab during the 2006–
2011 respiratory syncytial virus (RSV) seasons were recruited
across 30 sites. Respiratory illness events were captured
monthly. Infants ≤32 completed weeks gestational age (GA)
(Group 1) were compared to 33–35 completed weeks GA
infants (Group 2) following prophylaxis. In total, 6,654 patients
were analyzed (Group 1, n05,183; Group 2, n01,471). The
mean GAwas 29.9±2.9 versus 34.2±2.2 weeks for Groups 1
and 2, respectively. Group differences were significant (all
p-values <0.05) for the following: proportion of males, Cauca-
sians, siblings, multiple births, maternal smoking, smoking
during pregnancy, household smokers, >5 household individu-
als, birth weight, and enrolment age. Overall, infants received
92.6 % of expected injections. Group 1 received significantly
more injections, but a greater proportion of Group 2 received
injections within recommended intervals. The hospitalization
rates were similar for Groups 1 and 2 for respiratory illness
(4.7 % vs. 3.7 %, p00.1) and RSV (1.5 % vs. 1.4 %, p00.3).
Neither the time to first respiratory illness [hazard ratio00.9, 95
% confidence interval (CI) 0.7–1.2, p00.5] nor to first RSV
hospitalization (hazard ratio01.3, 95 % CI 0.8–2.2, p00.3)
were different. Compliance with RSV prophylaxis is high.
Despite the higher number of palivizumab doses in infants
≤32 completed weeks GA, the two groups’ respiratory illness
and RSV-positive hospitalization rates were similar.
Introduction
Respiratory syncytial virus (RSV) is an important viral
respiratory pathogen in children in terms of individual mor-
bidity and societal costs. The majority of children aged
<2 years have experienced an RSV-related illness, predom-
inantly during the winter months, but in some countries,
RSV exposure prevails throughout the entire year.
Palivizumab is a humanized monoclonal antibody indi-
cated for RSV prophylaxis in infants and children at high
risk, and has been shown to be safe and well tolerated [1].
The Canadian Paediatric Society and most international
pediatric position statements support prophylaxis for all
infants of ≤32 completed weeks gestational age (GA) [2–8].
Infants of 33–35 completed weeks GA comprise a significant
proportion of the annual birth cohort, and prophylaxis for this
group of infants is currently based on a composite of risk factors
or the use of validated risk factor models that specifically target
infants at moderate to high risk for severe RSV infection and
hospitalization [9–15]. In Canada, prophylaxis is recommended
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provincially for moderate- to high-risk 33–35 completed weeks
GA infants with the use of a risk scoring tool [7, 12].
Infants of 33–35 completed weeks GA have previously
been shown to have similar RSV-positive hospitalization rates
and incur morbidities and costs not indifferent to those infants
of ≤32 completed weeks GA [16–18]. There are limited data
systematically comparing the effects of prophylaxis on the
outcomes of infants in specific gestational age cohorts, fol-
lowing RSV-related hospitalization. The collection of long-
term data on seasonality, risk factors, and outcomes is neces-
sary in order to evaluate the impact of prophylaxis in everyday
practice and examine hospitalization rates in similar premature
populations globally.
The Canadian Registry of Palivizumab (CARESS) is a drug
registry that prospectively collects information on patient de-
mographics, including risk factors for RSV, palivizumab usage,
characteristics of each hospitalization for both respiratory illness
and RSV-positive respiratory infections, and compliance in any
patient receiving palivizumab. In addition, safety data on serious
adverse events possibly related to palivizumab are collected.
The primary objective of the present paper is to compare data on
premature infants without pre-existing medical disorders of ≤32
completed weeks GA (Group 1) to that of infants of 33–35
completed weeks GA (Group 2) within CARESS.
Methods
Any pediatric patient receiving at least one dose of palivizumab
in anyRSV season from 2006 to 2011was eligible for inclusion
[19]. Children were excluded if a parent or legal guardian could
not communicate in either English or French, or if the child had
received palivizumab as part of a clinical trial during the study
period. Only premature infants without underlying medical
disorders such as bronchopulmonary dysplasia (BPD), congen-
ital heart disease (CHD), neuromuscular impairments, cystic
fibrosis (CF), dysmorphologic syndromes, chromosomal
anomalies, and inherited disorders were included in this analy-
sis. This maintained comparability of the assembled cohorts by
avoiding potential confounding by known risk factors that
could increase the risk of RSV hospitalization. Group 1 infants
were ≤32 completed weeks GA, while Group 2 comprised
infants of 33–35 completed weeks GA. Group 2 infants qual-
ified for prophylaxis if they were considered moderate to high
risk for RSV infection and hospitalization. [12].
Subjects were enrolled by the treating physician and/or
research nurse. Following consent, baseline data were
obtained on patient demographics, prior medical history,
neonatal course, and details of current palivizumab admin-
istration. Follow-up telephone interviews were conducted
monthly until the end of the RSV season, obtaining data
on palivizumab administration, changes in baseline data,
and specific information regarding respiratory infections.
In the event of a hospitalization, and with parental consent,
the relevant hospital records were reviewed by the site’s
research nurse for detailed information on the criteria for
hospitalization, length of stay [regular ward vs. intensive care
unit (ICU)], days on respiratory support and/or intubation, and
type of RSV test performed and diagnosis, as reported in the
hospital discharge summary. The study was approved by the
research ethics board of each participating institution.
SPSS version 19.0 (SPSS Inc., Chicago, IL, USA) was
utilized to analyze data by standard descriptive methods,
comparative statistics [chi-square, analysis of variance
(ANOVA), and t-tests] and regression analysis. Premature
infants of ≤32 completed weeks GA (Group 1) were com-
pared to infants of 33–35 completed weeks GA (Group 2).
A p-value of less than 0.05 was considered to be significant.
The primary endpoint was the time to first RSV-positive
hospitalization. A Cox proportional hazards analysis was
conducted to determine the effect of group on the time to
first respiratory illness hospitalization and the time to first
RSV-positive hospitalization, as well as to examine the
effects of any potential covariates to be determined a priori.
Results
Subjects
Subjects were enrolled between October 2006 and May 2011.
A total of 10,092 infants were recruited in 30 geographically
located Canadian sites: five from Western Canada (British
Columbia, Alberta, Manitoba, or Saskatchewan), 22 from
Central Canada (Ontario, Quebec), and three from Eastern
Canada (New Brunswick, Newfoundland, Nova Scotia, or
Prince Edward Island). Of the 10,092 patients, 6,654 were
included in the analysis, with 5,183 subjects categorized into
Group 1 and 1,471 into Group 2. The demographic and
neonatal information of the infants is displayed in Table 1.
The average [± standard deviation (SD)] GA in Group 1 was
29.9±2.9 weeks, and it was 34.2±2.2 weeks in Group 2.
There were significant differences between the groups in
almost all demographic categories. Group 2 had a greater
proportion of males, a greater proportion with siblings, mul-
tiple births, a mother who smokes, a mother who smoked
during pregnancy, any smokers in the household, ≥2 smokers
in the household, >5 individuals in the household, and, on
average, the infants weighed more at birth (Table 1). Group 1
infants were more likely to be Caucasian, and, on average,
were older at enrolment (Table 1). Infants in Group 1 had
more complicated neonatal courses, with a greater percentage
requiring respiratory support and oxygen therapy. Group 1
infants also spent a longer length of time on respiratory
support and oxygen therapy. Finally, a greater proportion of
Group 1 infants had documented necrotizing enterocolitis,
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surgery for patent ductus arteriosus, and documented sepsis.
This is in keeping with their mean lower GA.
Utilization
A total of 26,540 injections were administered overall. An
average of 4.0±1.6 injections was given to each infant in
any single RSV season. Group 1 infants, on average, re-
ceived a greater number of injections in a season than Group
2 infants (4.1±1.6 vs. 3.7±1.5, p<0.0005).
Compliance
We defined compliance in two ways: expected number of
doses versus actual number received, and inter-dose interval.
For the expected number of doses, the calculation assumed
monthly injections from the first dose to the end of the RSV
season [11]. Overall, infants in both groups received 92.6±
27.9 % of the expected number of injections. Groups 1 and 2
received similar percentages of their expected injections (92.9
±27.9 % vs. 91.6±27.9 %, p00.12).
For the number of days between injections, intervals of
30±5 days were considered to be compliant. However, an
interval of 20±4 days between the first and second injec-
tions likely results in higher trough levels after the first dose,
potentially offering better RSV protection. Therefore, an
interval of 16–35 days between the first and second injec-
tions was considered to be compliant
A greater proportion of Group 2 infants received their
appropriate dose-interval injections than Group 1 (75.7 %
vs. 71.9 %, p00.003).
Respiratory illness and RSV-positive hospitalizations
RSV-positive hospitalizations and associated morbidities are
shown in Table 2. Apart from the mean age at the time of
admission to hospital, there were no differences evident
between the groups. The RSV-positive hospitalization rate
was calculated follows:
RSV positive hospitalization rate
¼ No: hospitalized for respiratory illness
Total no: of children
 No: of RSV positive children
Total no: of children tested
Table 1 Demographic and neonatal information
Group 1 (≤32 weeks GA), n05,183 Group 2 (33–35 weeks GA), n01,471 p-value
Demographic information
Mean gestational age (weeks ± SD) 29.9±2.9 34.2±2.2 <0.0005
No. of males (%) 2,837 (54.7) 937 (63.7) <0.0005
No. of Caucasians (%) 3,634 (70.1) 980 (66.6) 0.011
Mean age at enrolment (months ± SD) 3.7±2.9 2.3±2.8 <0.0005
Mean birth weight (g ± SD) 1,430±577 2,150±507 <0.0005
No. in daycare (%) 48 (0.9) 33 (2.2) <0.0005
No. with siblings (%) 2,897 (55.9) 1,146 (77.9) <0.0005
No. of multiple births (%) 1,795 (34.6) 575 (39.1) 0.002
No. with mother that smokes (%) 720 (13.9) 242 (16.5) 0.012
No. with mother that smoked during pregnancy (%) 698 (13.5) 235 (16.0) 0.015
No. with any smokers in the household (%) 1,378 (26.6) 493 (33.5) <0.0005
No. with ≥2 smokers at home (%) 524 (10.1) 218 (14.8) <0.0005
No. with >5 individuals in the household (%) 1,093 (21.1) 641 (43.6) <0.0005
No. with a history of atopy in the immediate family (%) 2,027 (39.1) 562 (38.2) 0.545
Neonatal information
Mean length of stay (days ± SD) 54.4±42.9 21.1±37.4 <0.0005
No. with respiratory support (%) 3,795 (73.2) 414 (28.1) <0.0005
Mean length of respiratory support (days ± SD) 19.3±24.8 3.8±5.9 <0.0005
No. with oxygen therapy (%) 3,119 (60.1) 356 (24.2) <0.0005
Mean length of oxygen therapy (days ± SD) 26.3±39.6 6.2±13.4 <0.0005
No. with documented necrotizing enterocolitis (%) 215 (4.1) 15 (1.0) <0.0005
No. with surgery for patent ductus arteriosus (%) 242 (4.7) 6 (0.4) <0.0005
No. with documented sepsis (%) 908 (17.5) 57 (3.8) <0.0005
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Overall, 297 infants were hospitalized 339 times for
respiratory illnesses, giving a hospitalization incidence rate
of 4.5 %. Of these, 243 were tested for RSV, and 80 were
positive, giving an overall RSV-positive hospitalization rate
of 1.47 %. Groups 1 and 2 did not have significantly
different hospitalization rates for respiratory-related events
(4.7 % vs. 3.7 %, p00.1) nor RSV-positive infections (1.5 %
vs. 1.4 %, p00.3). Group allocation (Group 1 vs. Group 2)
also did not have a significant effect on the time to first
hospitalization [hazard ratio00.9, 95 % confidence interval
(CI) 0.7–1.2, p00.5] nor on the time to first RSV-positive
hospitalization (hazard ratio01.3, 95 % CI 0.8–2.2, p00.3)
(Fig. 1).
Table 3 describes the demographic differences between
infants who were hospitalized with an RSV infection and
those who were either not hospitalized or who had a non-
RSV-positive hospitalization. A greater proportion of hos-
pitalized infants had siblings, a mother who smokes, smok-
ers at home, >5 individuals in the household, and a history
of atopy in the immediate family. A Cox proportional haz-
ards analysis found that each of these risk factors indepen-
dently had a significant effect on the time to first RSV-
positive hospitalization (siblings: hazard ratio02.5, 95 %
CI 1.3–4.8, p00.004; >5 individuals in the household: haz-
ard ratio02.1, 95 % CI 1.8–3.3, p00.003; history of atopy:
hazard ratio02.3, 95 % CI 1.4–3.7, p00.001; smokers:
hazard ratio01.7, 95 % CI 1.0–2.6, p00.035). Interestingly,
cumulative risk factors in an individual infant significantly
increased the hazard ratio (Fig. 2), from 4.3 (95 % CI 1.0–
18.8) with one risk factor to 24.3 (95 % CI 5.1–114.6) with
four risk factors. However, the Cox proportional hazards
analysis showed no effect of group allocation (p00.640),
even when the number of risk factors are taken into consid-
eration (model: chi-square047.21, df02, p<0.0005).
Discussion
RSV-related hospitalization rates for premature infants of
≤35 weeks GA range from 11 to 28 % [20–25] and are not
indifferent across the gestational age group strata. Boyce et
al., in a retrospective Tennessee Medicaid study, reported
that infants of <28 weeks, 29–32 weeks, and 33–35 weeks
GA compared to healthy term enrollees had RSV hospital-
izations per 1,000 child years of the RSV season of 187.5,
163.6, and 159.6 versus 88.2, respectively [21]. Similarly,
Heikkinen et al. determined RSV hospitalizations in preterm
infants <2 years of age from 1991–2000 and documented an
incidence of 7 % in those who were <28 weeks GA (n0
168), 7 % in 29–32 weeks GA (n0498), and 4 % in prema-
ture infants 33–35 weeks GA (n01,133) [26]. Apnea may
be a marker of RSV disease severity in young infants [27,
28], but the risk could not be quantified in a systematic
review [29]. Schiller et al. noted that, of 31 preterm infants
admitted to the pediatric ICU between 2004 and 2007, the
incidence of central apnea ranged from 3.2 % (<28 weeks
GA) to 32.3 % (28–32 weeks GA) and 64.5 % (33–36 weeks
GA) [30]. Additionally, data on morbidities and outcomes in
33–35 weeks GA infants following an RSV illness indicate
that they are similar or worse than those born at ≤32 weeks
in terms of rates of apnea, intubation, ventilation, oxygen
supplementation, systemic complications, ICU admission,
hospital and ICU length of stay, and median costs for patient
care [16–18]. In a matched-control study of 32–35 weeks
GA infants hospitalized with RSV, follow-up healthcare
resource utilization up to a mean of 2.1 years of age was
significantly higher in index cases, with a higher incidence
of overall accompanying mortality and sudden or unex-
plained death [31]. Following hospitalization of 32–
35 weeks GA infants with RSV, parents’ health-related
quality of life is also significantly impacted, with more
and longer time off work for child care, excess workload
related to infant illness, and burden associated with lower
scores in physical activities of daily living [32]. Fatalities for
hospitalized premature infants across 36 published studies
(1966–2009) are between 0 and 6.1 % [33] and low birth
weight <2,500 g is an independent risk factor for mortality
from bronchiolitis [34].
The safety and efficacy of RSV prophylaxis in the reduc-
tion of RSV hospitalizations has been demonstrated in a
Table 2 Respiratory syncytial
virus (RSV)-positive
hospitalizations
Group 1 (≤32 weeks
GA), n062
Group 2 (33–35 weeks
GA), n018
p-value
Mean age at admission (months ± SD) 4.9±2.8 2.8±2.5 0.004
Mean length of stay (days ± SD) 6.7±5.4 5.2±5.0 0.276
No. requiring intubation (%) 4 (6.5) 1 (5.6) 1.000
Mean length of intubation (days ± SD) 0.5±2.2 0.2±0.9 0.556
No. requiring respiratory support (%) 14 (22.6) 4 (22.2) 1.000
Mean length of respiratory support (days ± SD) 1.3±2.9 0.3±1.8 0.184
No. admitted to ICU (%) 16 (25.8) 5 (27.8) 1.000
Mean length of ICU stay (days ± SD) 1.2±2.7 1.3±2.4 0.906
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Fig. 1 Cox proportional hazard
curves depicting the effect of
group allocation on the time to
hospitalization for respiratory
illness (a) and respiratory
syncytial virus (RSV)-positive
infection (b), comparing infants
of ≤32 completed weeks
gestational age (GA; solid lines)
and those of 33–35 completed
weeks GA (dotted lines).
Group allocation did not have
an effect in either case
[respiratory illness: hazard
ratio00.9, 95 % confidence
interval (CI) 0.70–1.2, p00.5;
RSV-positive infection:
hazard ratio01.3, 95 % CI
0.8–2.2, p00.3]
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randomized, double-blind, clinical trial, and is more signif-
icant for infants of 32–35 weeks GA without BPD (80 %
reduction over placebo, p00.002) compared to infants of
<32 weeks GA (47 % reduction over placebo, p00.003) [1].
While the use of prophylaxis has been adopted almost
universally for infants of <32 weeks GA, there has been a
guarded approach to RSV immunization in the 33–35 weeks
GA cohort, despite the supportive scientific evidence. This
is not surprising, because palivizumab is costly and this
group comprises a significant proportion of annual births
which has steadily climbed over recent years universally,
given the increasing number of deliveries of late preterm
infants. However, the use of specific risk factors weighted
against the risk of RSV-positive hospitalization [10, 11] or
validated risk models based on defined variables has stream-
lined a more conservative, cost-effective prophylaxis pro-
gram for 33–35 weeks GA infants [12, 13, 35–37].
In our study, RSV-positive hospitalization rates for
infants of both ≤32 and 33–35 weeks GA following
prophylaxis were similar at 1.5 and 1.4 %, respectively, and
were lower than similar groups in the treated arm of the
IMpact trial (5.8 and 1.8 %, respectively), despite a three-
fold greater sample size [1]. This real-world experience of
the improved effectiveness of palivizumab was also noted in
the United States Outcomes Registry, which realized higher
hospitalization rates of 1.84 % for infants of <32 weeks GA
(n07,786) and lower rates of 0.83 % for infants of 32–
35 weeks GA (n09,294), respectively, with significantly
higher numbers of recruited infants who had similar gesta-
tional ages and pre-existing medical disorders such as CHD,
BPD, and CF [38]. The risk scoring tool, or a modified
version thereof, is used in all of the Canadian provinces to
target RSV prophylaxis cost-effectively for 33–35 weeks
GA infants who are considered to be at moderate to high risk
(risk score 49–100) for RSV hospitalization [12]. This may
account for the difference in RSV-positive hospitalization
rates compared to the United States Outcomes Registry [38].
Of interest, the overall compliance in our study relative to the
expected number of palivizumab doses and 30±5 day dose
intervals during the RSV season was higher at 92.6 % ±
27.9 % versus 79.9 to 82.7 % and 71.9 to 75.7 % versus
65.2 to 69.5 %, respectively, in the United States Outcomes
Registry, which may further explain some of the differences in
the RSV-related hospitalization rates [38].
Several environmental and demographic risk factors are
associated with severe RSV infection and subsequent
Table 3 Demographic and neonatal information for patients who were and were not hospitalized for an RSV infection
RSV-positive hospitalization, n080 Non-RSV-positive hospitalization
or not hospitalized, n06,574
p-value
Demographic information
Mean gestational age (weeks ± SD) 30.5±3.2 30.9±3.3 0.260
No. of males (%) 42 (52.5) 3,732 (56.8) 0.429
No. of Caucasians (%) 60 (75.0) 4,554 (69.3) 0.329
Mean age at enrolment (months ± SD) 3.0±2.0 3.4±2.9 0.259
Mean birth weight (g ± SD) 1,598±957 1,589±631 0.901
No. in daycare (%) 0 (0) 81 (1.2) 0.628
No. with siblings (%) 66 (82.5) 3,977 (60.5) <0.0005
No. of multiple births (%) 34 (42.5) 2,336 (35.5) 0.198
No. with mother that smokes (%) 19 (23.8) 944 (14.4) 0.023
No. with mother that smoked during pregnancy (%) 17 (21.3) 916 (13.9) 0.074
No. with smokers in the household (%) 32 (40.0) 1,839 (28.0) 0.024
No. with ≥2 smokers at home (%) 13 (16.3) 729 (11.1) 0.151
No. with >5 individuals in the household (%) 35 (43.8) 1,699 (25.8) 0.001
No. with a history of atopy in the immediate family (%) 48 (60.0) 2,541 (38.7) <0.0005
Neonatal information
Mean length of stay (days ± SD) 54.6±46.9 46.7±44.0 0.128
No. with respiratory support (%) 54 (67.5) 4,155 (63.2) 0.485
Mean length of respiratory support (days ± SD) 25.3±27.4 17.7±24.0 0.022
No. with oxygen therapy (%) 49 (61.3) 3,426 (52.1) 0.115
Mean length of oxygen therapy (days ± SD) 28.3±35.1 24.2±38.3 0.462
No. with documented necrotizing enterocolitis (%) 4 (5.0) 226 (3.4) 0.358
No. with surgery for patent ductus arteriosus (%) 8 (10.0) 240 (3.7) 0.010
No. with documented sepsis (%) 14 (17.5) 951 (14.5) 0.425
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hospitalization. These invariably include prematurity, sex,
household crowding, daycare attendance, exposure to tobac-
co smoke and maternal smoking during pregnancy, young
siblings, chronological age and birth early during the RSV
season, intrauterine growth restriction, familial atopy and
asthma, and short duration of breast feeding [4, 10, 11, 13,
39–45]. We established that, in premature infants of
<35 weeks GA who had received palivizumab, similar risk
factors such as having siblings, >5 individuals in the house-
hold, a history of atopy in the immediate family, and smok-
ing in the household also determined the time to first RSV
hospitalization. The effect of each risk factor was indepen-
dently significant and was augmented six-fold as the num-
ber of risk factors cumulatively rose from 1 to 4 in an
individual patient. Our study confirms the relationship be-
tween environmental smoke exposure and RSV lower res-
piratory tract infection hospitalization, which is similar to
other documented reports, but the effect is not uniformly
consistent across published studies [46–48] because the
association is likely related to the dose and concentration
of circulating cigarette smoke extract [49, 50].
The limitations of our study include the absence of control
groups for infants who received prophylaxis, which affected
our ability to interpret the magnitude of the reduction in RSV
hospitalization, apart from comparisons with historical con-
trols from the IMpact study [1]. Subjects of 33–35 weeks GA
and considered to be low risk (score 0–48) are not enrolled in
the CARESS database and, therefore, we cannot draw any
conclusions on the outcomes of this cohort. However, in a
previous study involving 430 infants of 33–35 weeks GA, the
low-risk group comprised 81 % of the patients, of whom only
1.4 % were hospitalized with an RSV infection [51].
In summary, this is the largest study that determined the
outcomes of premature infants of ≤35 completed weeks GA
without underlying medical disorders who received prophy-
laxis in a single RSV season over four consecutive years.
RSV hospitalizations were similar for infants of ≤32 weeks
GA and those between 33 and 35 weeks GA, despite the
greater number of doses received by infants of ≤32 weeks
GA. The low hospitalization rate could be, in part, related to
the high compliance achieved with infants receiving 92.6 %
of their expected number of injections and the higher
Fig. 2 Cox proportional hazard curves illustrating the number of risk factors that had a significant effect on the time to first RSV-positive
hospitalization: having siblings, >5 individuals in the household, a history of atopy in the immediate family, and smoking in the household
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efficacy of palivizumab, as demonstrated in the original
randomized controlled trial [1]. RSV prophylaxis of infants
of 33–35 weeks GA is both beneficial and cost-effective, but
should be rationalized based on country-specific epidemio-
logical data, local financial budgets and funding availability,
and should be strategized to target the highest risk infants in
this sub-population.
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